These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36598526)

  • 1. [Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases].
    Gallwitz B
    Inn Med (Heidelb); 2023 Feb; 64(2):205-210. PubMed ID: 36598526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
    Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
    Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
    Nogueiras R; Nauck MA; Tschöp MH
    Nat Metab; 2023 Jun; 5(6):933-944. PubMed ID: 37308724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
    Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
    Lisco G; De Tullio A; Disoteo O; De Geronimo V; Piazzolla G; De Pergola G; Giagulli VA; Jirillo E; Guastamacchia E; Sabbà C; Triggiani V
    Front Endocrinol (Lausanne); 2022; 13():920541. PubMed ID: 36157450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
    Gallwitz B
    Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
    Jakubowska A; Roux CWL; Viljoen A
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):12-22. PubMed ID: 38356208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapy for the treatment of bone fragility in diabetes mellitus.
    Mabilleau G; Gobron B; Bouvard B; Chappard D
    Peptides; 2018 Feb; 100():108-113. PubMed ID: 29412811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
    Goldenberg RM; Teoh H; Verma S
    Curr Opin Cardiol; 2023 Nov; 38(6):539-545. PubMed ID: 37792556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Gut-Bone Axis in Diabetes.
    Maagensen H; Helsted MM; Gasbjerg LS; Vilsbøll T; Knop FK
    Curr Osteoporos Rep; 2023 Feb; 21(1):21-31. PubMed ID: 36441432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.